

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
737 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE

93 AUG 16 PM 3:43

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

H. D.

1. Registrant Name Pfizer, Inc.			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 325 7th Street, N.W. Suite 1200 City Washington State/Zip (or Country) DC 20004			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name M. Kenneth Bowler		Telephone _____ E-mail (optional) _____	5. Senate ID # 31326-12
7. Client Name <input checked="" type="checkbox"/> Self		6. House ID # 31354000	

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____ 11. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	\$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$1,950,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options. <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature *Terence J. Gallagher* Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 1 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code AGR (one per page)

16. Specific Lobbying issues

H.R. 1906 and S. 1233, Agriculture Appropriations, (FDA Funding and Risk Assessment for Animal Drugs)

Animal Health Issues

Antibiotic Resistance

CVM Proposed Framework for Evaluating and Assuring the Human Safety of Microbial Effects of New Animal Drugs

Intended for use in Food-Producing Animals

17. House(s) of Congress and Federal agencies contacted Check if None


House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Mullen, Heather M.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 2 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)


16. Specific Lobbying issues
H.R. 1906/S. 1233, Agriculture Appropriations, (FDA Funding and Animal Health Issues)
H.R. 2084, S. 1143, Transportation Appropriations, (Study on Nonseating Medications)
H.R. 2670, S. 1217, Commerce, Justice, State Appropriations, (New York Botanical Gardens)
H.R. 2684, VA/HUD Appropriations, (VA Healthcare System Reform and Drug Formulary)
No bills, Labor/HHS Appropriations, (Medicaid Pharmaceutical Coverage and NIH Funding Issues)

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
Department of State
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 3 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.


15. General issue area code CPT (one per page)
16. Specific Lobbying issues
(Not Yet Introduced), "The Pharmaceutical Testing Equalization Act of 1999",
H.R. 1598 and S. 1172, "The Patent Fairness Act", (patent term restoration)
H.R. 1997, "The American Inventors Protection Act", (patent term restoration and Patent Office reforms)
Amendments to Hatch-Waxman Act (no bills)
Intellectual Property Protection Issues (no bills)

17. House(s) of Congress and Federal agencies contacted Check if None
Congressional Budget Office
Department of Commerce
Department of State
House of Representatives
Patent and Trademark Office
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 4 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)


16. Specific Lobbying issues
H.R. 1875 and S. 353, Class Action Jurisdiction Act,

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bennett, Catherine F.</u>		<u>No</u>
<u>Boyd, Michael D.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 5 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)


16. Specific Lobbying issues
S. 1090, H.R. 1300, Superfund Reauthorization,
S. 547, H.R. 2520, "Credit for Voluntary Reductions Act",

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Commerce
Department of State
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bowler, M. Kenneth</u>		<u>No</u>
<u>Boyd, Michael D.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 6 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying Issues

H.R. 1885, S. 1191, "The International Prescription Drug Parity Act", (Drug Safety)
H.R. 2116, "Veterans' Millenium Health Care Act", (System Reform Issues)
H.R. 358, S. 1256, H.R. 448, S. 326, Health Care/Managed Care Bills,
H.R. 664, S. 731, "The Prescription Drug Fairness for Seniors Act of 1999", (Government Price Controls)
S. 841, H.R. 1495, H.R. 1796, H.R. 696, H.R. 1109,, Medicare Prescription Drug Benefit Bills,
S. 881, H.R. 2470, S. 573, H.R. 1057, Confidentiality of Medical Information,
Breaux/Thomas Premium Support for Medicare
President Clinton's Plan for Strengthening and Modernizing Medicare for the 21st Century

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services
Department of Veterans Affairs
Food & Drug Administration
General Accounting Office
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No
Miller, Michael D.		No
Mullen, Heather M.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Terence J. Gallagher* Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 7 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM..... (one per page)


16. Specific Lobbying issues
S. 841, H.R. 1495, H.R. 1796, H.R. 1109, Medicare Prescription Drug Benefit Bills, Breaux/Thomas Premium Support for Medicare President Clinton's Plan for Strengthening and Modernizing Medicare for the 21st Century

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Health & Human Services
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bennett, Catherine P.</u>		<u>No</u>
<u>Bowler, M. Kenneth</u>		<u>No</u>
<u>Boyd, Michael D.</u>		<u>No</u>
<u>Miller, Michael D.</u>		<u>No</u>
<u>Mullen, Heather M.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 8 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)
16. Specific Lobbying issues
H.R. 2488, Financial Freedom Act of 1999, (R&D Tax Credit, Issues affecting international tax, Medicare prescription drug provision)

17. House(s) of Congress and Federal agencies contacted Check if None
Department of Treasury
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Bennett, Catherine P.</u>		<u>No</u>
<u>Bowler, M. Kenneth</u>		<u>No</u>
<u>Boyd, Michael D.</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99
Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 9 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Item	Description	Data
16	Lobbying Issues	Tax Reform Issues (no bills) Foreign Tax Deferral (no bills) Foreign Tax Credit (no bills) Medical Innovation Tax Credit (no bills) Executive Compensation Issues (no bills) Section 936 (no bills) Section 956 (no bills) Notice 98-11 (no bills)

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.


15. General issue area code TRA (one per page)
16. Specific Lobbying issues
**H.R. 2084, S. 1143, Transportation Appropriations, (Study on Nonsedating Medications)
DOT Study of Safe Use of Medications by Commercial Truck Drivers**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Boyd, Michael D.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 11 of 14

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

- H.J. Res. 58, Resolution of Disapproval of Jackson-Vanik Waiver for Vietnam,
- H.J. Res. 57, Resolution of Disapproval of Normal Trade Relations for China,
- H.R. 1885, S. 1191, "The International Prescription Drug Parity Act", (Safety of Imported Drugs)
- International Intellectual Property Protection Issues (no bills)
- WTO Implementation Issues (no bills)
- International Pharmaceutical Market Access Issues (no bills)


17. House(s) of Congress and Federal agencies contacted Check if None

- Department of Agriculture
- Department of State
- Department of Transportation
- Department of Treasury
- Executive Office of the President
- House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Bennett, Catherine P.		No
Bowler, M. Kenneth		No
Boyd, Michael D.		No

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature  Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 12 of 14

Registrant Name: **Pfizer, Inc.**

Client Name: **Pfizer, Inc.**

Item	Description	Data
17a	House of Congress/Agencies	Senate
17a	House of Congress/Agencies	United States Trade Representative

Registrant Name: Pfizer, Inc.

Client Name: Pfizer, Inc.

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

IMM, MED, RET, SCI

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Signature *Terence J. Gallagher* Date 8/12/99

Printed Name and Title Terence J. Gallagher - Vice President, Corporate Governance Page 14 of 14